
News|Articles|January 1, 2004
Advair Diskus 250/50 (Fluticasone 250 µg and salmeterol 50 µg inhalation powder)
Novel therapy for COPD
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patients may not see savings from new Medicare drug programs
2
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
3
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
4
FDA accepts NDA for gedatolisib, Celcuity’s investigational breast cancer treatment
5




















































